Skip to main content

Liptruzet Side Effects

Generic name: atorvastatin / ezetimibe

Medically reviewed by Last updated on Jan 28, 2024.

Note: This document contains side effect information about atorvastatin / ezetimibe. Some dosage forms listed on this page may not apply to the brand name Liptruzet.

Applies to atorvastatin / ezetimibe: oral tablet.


You should not use this medicine if you have active liver disease or abnormal liver function tests.

Do not use atorvastatin and ezetimibe if you are pregnant or if you could become pregnant. Use effective birth control.

Do not breast-feed while using this medicine.

Get emergency medical help if you have any of these signs of an allergic reaction while taking atorvastatin / ezetimibe: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

In rare cases, atorvastatin can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have unexplained muscle pain, tenderness, or weakness especially if you also have fever, unusual tiredness, and dark colored urine.

Stop using this medicine and call your doctor at once if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to atorvastatin / ezetimibe: oral tablet.


The more commonly reported adverse reactions have included increased ALT, increased AST, and musculoskeletal pain.[Ref]


Common (1% to 10%): ALT increased (5%), AST increased (4%)

Postmarketing reports: Hepatitis, cholelithiasis, cholecystitis, fatal and nonfatal hepatic failure[Ref]


Common (1% to 10%): Musculoskeletal pain (3.8 to 4%), arthralgia (3 to 6.9%), pain in extremity (2.7 to 6%), myalgia (3.5%), muscle spasms (3%), muscle weakness (2%)

Postmarketing reports: Myopathy/rhabdomyolysis, necrotizing myopathy (rarely), injury, poisoning and procedural complication, tendon rupture, myositis[Ref]


Common (1% to 10%): Diarrhea (4.1 to 6.8%), abdominal pain (3%), nausea (3 to 4%), dyspepsia (4.7%)[Ref]

Nervous system

Common (1% to 10%): Dizziness (2 to 6%), insomnia (3%), fatigue (2.4%)

Postmarketing reports: Headache, paraesthesia, peripheral neuropathy, amnesia, memory impairment, confusion, depression, dizziness[Ref]


Common (1% to 10%): Hyperkalemia (2%)[Ref]


Common (1% to 10%): Hot flushes (2%)[Ref]


Common (1% to 10%): Urinary tract infection (5.7%)[Ref]


Postmarketing reports: Thrombocytopenia, elevated creatine phosphokinase[Ref]


Postmarketing reports: Anaphylaxis, hypersensitivity reactions[Ref]


Common (1% to 10%): Influenza (2%)[Ref]


Common (1% to 10%): Coughing (2 to 3%), bronchitis (2%), sinusitis (2 to 2.8%), upper respiratory tract infection (4.3%), nasopharyngitis (up to 8.3%), pharyngolaryngeal pain (up to 2.3%)

Postmarketing reports: Interstitial lung disease[Ref]


Postmarketing reports: Fatigue


Postmarketing reports: Angioedema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rash, urticaria[Ref]


1. Cerner Multum, Inc. Australian Product Information.

2. Product Information. Liptruzet (atorvastatin-ezetimibe). Merck & Co., Inc. 2013.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.